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1. Introduction 
1.1 History of β2-glycoprotein I 
ǃ2-Glycoprotein I (ǃ2GPI) was described in literature for the first time in 1961 (Schultze et al., 
1961) and seven years later the first 2GPI deficient, seemingly healthy individual was 
identified (Haupt et al., 1968). ǃ2GPI’s alternative name, apolipoprotein H, suggests a 
function in lipid metabolism, but this was based on a single publication that dates from 1979 
in which it was shown that ǃ2GPI was distributed over different human lipoproteins (Polz & 
Kostner, 1979). Since 1983, the names ǃ2GPI and apolipoprotein H were used side by side for 
the same protein (Lee et al., 1983), and the official designation for the ǃ2GPI gene has 
become APOH. From 1990 on, the interest in this protein has increased significantly when 
ǃ2GPI was identified as the most important antigen in the antiphospholipid syndrome, 
which is amongst others characterized by the presence of antibodies directed to ǃ2GPI 
(McNeil et al., 1990; Galli et al., 1990). In 2010, a second three-dimensional conformation of 
ǃ2GPI was identified (Ağar et al., 2010) besides the known fishhook-like conformation that 
was suggested by the crystal structure of the protein (Bouma et al., 1999; Schwarzenbacher 
et al., 1999). In this chapter we will focus on this novel conformation of ǃ2GPI and discuss 
the consequences of the transition between the two conformations for ǃ2GPI on past but also 
on present findings.  
1.2 Biochemistry of β2-glycoprotein I 
ǃ2GPI is a 43 kDa protein and consists of 326 amino acid residues (Lozier et al., 1984). ǃ2GPI 
is synthesized in the liver and it circulates in blood at variable levels (Rioche et al., 1974). 
ǃ2GPI is an anionic phospholipid binding glycoprotein composed of five homologous 
complement control protein repeats, CCP-I to CCP-V (Bouma et al., 1990; Schwarzenbacher 
et al., 1990). These CCPs are generally found in proteins from the complement system and 
mediate binding of complement factors to viruses and bacteria (Breier et al., 1970; Pangburn 
& Rawal, 2002). The first four domains contain approx. 60 amino acids each, whereas the 
fifth domain has a 6 residue insertion and an additional 19 amino acid C-terminal extension. 
The extra amino acids are responsible for the formation of a large positive charged patch 
within the fifth domain of ǃ2GPI (Hunt et al., 1993) that forms the binding site for anionic 
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phospholipids (Figure 1).The crystal structure of ǃ2GPI has been solved in 1999 by two 
groups (Bouma et al., 1990; Schwarzenbacher et al., 1990), and revealed a structure that 
resembles a J-shaped fishhook. The phospholipid binding site is located at the bottom side 
of CCP-V and consists of two major parts, a large positive patch of 14 charged amino acid 
residues and a flexible hydrophobic loop. This flexible loop has the potential to insert into 
membranes (Planque et al., 1999). 
1.3 β2-Glycoprotein I and the antiphospholipid syndrome 
The antiphospholipid syndrome (APS) is an auto-immune disease defined by the presence 
of antiphospholipid antibodies in blood of patients in combination with thrombotic 
complications in arteries or veins as well as pregnancy-related complications (Miyakis et al., 
2006). In APS patients, the most common venous event is deep vein thrombosis and the 
most common arterial event is stroke. In pregnant women with APS early and late 
miscarriages can occur (Eswaran & Rosen, 1985). Next to miscarriages also placental 
infarctions, early deliveries and stillbirth have been reported (Lockshin et al., 1985; Branch et 
al., 1989; Birdsall et al., 1992). Antiphospholipid antibodies often occur transiently after 
infectious diseases, but there is a general consensus that these transient auto-antibodies are 
not related to an increased thrombotic risk (Miyakis et al., 2006). The syndrome occurs more 
in women than in men, and is most common in young to middle-aged adults but can also 
occur in children and the elderly. Among patients with systemic lupus erythematodes or 
lupus, the prevalence of antiphospholipid antibodies ranges from 12 to 30% for 
anticardiolipin antibodies, and 20 to 35% for lupus anticoagulant antibodies (Gezer et al., 
2003). It is now generally accepted that the relevant auto-antibodies are not directed against 
phospholipids, but towards proteins bound to these phospholipids (Galli et al., 1990; McNeil 
et al., 1990; Bevers & Galli, 1990). ǃ2GPI has a relative low affinity towards these negatively 
charged phospholipids but its affinity increased more than 100-fold in the presence of auto-
antibodies. Anti-ǃ2GPI antibodies were found to be the most prominent auto-antibodies in 
APS (de Groot & Meijers, 2011). Recently, three independent groups  have shown the 
importance of antibodies against ǃ2GPI (Pierangelli et al., 1999; Jankowski et al., 2003; Arad 
et al., 2011) Mice that were challenged by injection of antiphospholipid antibodies had 
increased thrombus formation and foetal resorption (García et al., 1997; Ikematsu et al., 
1998). Despite the wealth of data on the role of ǃ2GPI in the pathophysiology of APS, there 
were no convincing indications that help our understanding of the function of ǃ2GPI in 
normal physiology. 
2. Conformations of β2-glycoprotein I 
2.1 β2GPI exists in two conformations 
There is overwhelming evidence that antibodies against ǃ2GPI can induce thrombosis in 
animal models (Blank et al., 1991; Pierangelli et al., 1999; Jankowski et al., 2003, Arad et al. 
2011), but it was unclear which metabolic pathway was disturbed by the auto-antibodies. 
Nevertheless, the ǃ2GPI protein itself must hold an important functional clue that could   
lead us to both its function and its role in the antiphospholipid syndrome. Since patients 
with antiphospholipid antibodies do not have circulating antibody-antigen complexes 
despite the presence of  large amounts of ǃ2GPI and antibodies in the circulation, the epitope 
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for the auto-antibodies on ǃ2GPI must be cryptic. As a consequence, the conformation of 
ǃ2GPI in plasma must be different from the one coated on an ELISA tray in tests for the 
detection of antibodies. The crystal structure of ǃ2GPI revealed a fishhook-like shape of the 
molecule (Bouma et al., 1990; Schwarzenbacher et al., 1990) (Figure 1). Part of the epitope 
that is recognized by auto-antibodies is located in the first domain of ǃ2GPI (Iverson et al., 
1998; de Laat et al., 2006). The crystal structure indicated that these amino acids are 
expressed on the surface of domain I of ǃ2GPI and should thus be accessible for auto-
antibodies. But the lack of binding of antibodies to ǃ2GPI in solution fits better with a 
circular structure of ǃ2GPI, a structure that was originally suggested by Koike et al. (1998). 
Electron microscopy (EM) studies showed that when antibodies were bound to ǃ2GPI, the 
protein indeed showed a fishhook-like shape, but native ǃ2GPI in the absence of antibodies 
showed a closed ‘circular’ shape (Figure 2) in which domains I and V interact with each 
other (Agar et al., 2010). 
 
 
 
In blue the negatively charged amino acids are depicted and in red the positively charged amino acids. 
In yellow the large positive charged patch is shown within the fifth  
domain of ǃ2GP that forms the binding site for anionic phospholipids. Picture was made  
using Cn3D version 4.1, produced by the National Center for Biotechnology Information 
(http://www.ncbi.nlm.nih.gov). 
Fig. 1. Crystal structure of ǃ2GPI with the five CCP domains (CCP-I to CCP-V). 
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(A) Purified plasma ǃ2GPI in the presence of antibodies directed against domain I of ǃ2GPI 
shows on magnification an open fishhook-like shape of ǃ2GPI. (B) Magnification of purified 
plasma ǃ2GPI shows a circular conformation of the protein. This figure was modified from 
work originally published in Blood. C. Agar, G.M.A. van Os, M. Mörgelin, R.R. Sprenger, 
J.A. Marquart, R.T. Urbanus, R.H.W.M. Derksen, J.C.M. Meijers, P.G. de Groot. ǃ2-
Glycoprotein I can exist in 2 conformations: implications for our understanding of the 
antiphospholipid syndrome. Blood 2010;116(8):1336-1343. © the American Society of 
Hematology. 
Fig. 2. Electron microscopy analysis of ǃ2GPI. 
By changing pH and salt concentrations, it was possible to convert ǃ2GPI from the native 
closed conformation into the open conformation and back (Agar et al., 2010). Analysis of EM 
pictures showed that more than 99% of plasma ǃ2GPI was in a closed conformation. These 
observations suggested that plasma ǃ2GPI circulates in a circular (closed) conformation, 
whereas after interaction with antibodies ǃ2GPI undergoes a major conformational change 
into a fishhook-like (open) structure. 
2.1.1 Effect of the conformation of β2GPI on coagulation 
ǃ2GPI is present in high concentrations in plasma, and depletion of ǃ2GPI from normal 
plasma does not influence the results of coagulation assays (Oosting et al., 1992; Willems et 
al., 1996). When antibodies toward ǃ2GPI were added to plasma, clotting times prolonged in 
a ǃ2GPI-dependent way. This effect of anti–ǃ2GPI antibodies is known as lupus 
anticoagulant (LA) activity. A LA could also be seen with open ǃ2GPI (Agar et al., 2010). 
When closed native ǃ2GPI was added to normal plasma or ǃ2GPI-depleted plasma, no effect 
on an activated partial thromboplastin time (aPTT)-based clotting assay was observed. 
A B 
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When open ǃ2GPI was added to plasma or ǃ2GPI-depleted plasma, the aPTT prolonged. 
Addition of antibody and open ǃ2GPI together to normal plasma gave an additional 
anticoagulant effect on top of the effect of open ǃ2GPI alone (Agar et al., 2010). The presence 
of ǃ2GPI in a certain conformation is dependent on the presence of anionic surfaces but also 
on the method of purification of ǃ2GPI. As was described by Agar et al (2010), the 
conformation of ǃ2GPI is dependent on the pH and salt concentration used during the 
purification of native ǃ2GPI. The structure of ǃ2GPI needs confirmation before doing 
experiments with purified ǃ2GPI. 
Schousboe (1985) was the first who described ǃ2GPI as a plasma inhibitor of the contact 
activation of the intrinsic blood coagulation pathway. With the current knowledge of the 
two conformations (Agar et al., 2010), these studies were most likely performed with the 
open conformation of ǃ2GPI, the only conformation that gives a prolongation in an aPTT. 
Furthermore, it was suggested that ǃ2GPI inhibited coagulation by inhibition of activation of 
coagulation factor XII (Henry et al., 1988) and coagulation factor XI (Shi et al., 2004). It is 
likely, that also these observations were obtained with the open ‘activated’ conformation of 
ǃ2GPI. The purification method that all these groups used included the use of perchloric 
acid, and these harsh conditions may have induced a conformational change of closed 
native ǃ2GPI into the open activated conformation of ǃ2GPI. It is highly recommended that 
the conformation of ǃ2GPI is confirmed in coagulation tests or by electron microscopy. It is 
expected that in the near future specific immunological assays will become available to 
determine the specific conformational state of ǃ2GPI. 
2.2 Functional consequence of the conformations of β2GPI 
Lipopolysaccharide (LPS), a major constituent of the outer membrane of Gram-negative 
bacteria, plays a role in activating the hosts’ immune response by binding to white blood 
cells (van der Poll & Opal, 2008). Analysis of electron microscopy pictures of ǃ2GPI 
incubated with LPS, showed that LPS was bound to domain V of ǃ2GPI and thereby induced 
a conformational change to the open conformation of ǃ2GPI (Figure 3) and showed the same 
fishhook-like shape when ǃ2GPI was bound to anionic surfaces or antibodies (Agar et al., 
2011a).  
A functional consequence of ǃ2GPI binding to LPS was investigated in an in vitro cellular 
model of LPS-induced tissue factor (TF) expression. Native plasma-purified ǃ2GPI dose-
dependently inhibited LPS induced TF expression both in monocytes and endothelial cells 
(Agar et al., 2011a). Furthermore, in an ex vivo whole blood assay ǃ2GPI inhibited LPS 
induced interleukin-6 expression, an inflammatory marker in innate immunity. 
Furthermore, an in vivo relevance was found of the interaction between ǃ2GPI and LPS in 
plasma samples of 23 healthy volunteers intravenously challenged with LPS (de Kruif et al., 
2007). A reduction of 25% of baseline values was observed of ǃ2GPI immediately after LPS 
injection, suggesting an in vivo interaction between ǃ2GPI and LPS. 
Also, a highly significant, negative association was found between plasma levels of ǃ2GPI 
and plasma levels of inflammatory markers TNFǂ, IL-6 and-IL-8 after the LPS challenge. In 
agreement to this, there was a highly significant inverse relation between the baseline ǃ2GPI 
levels and the observed temperature rise upon LPS challenge (Agar et al., 2011a). 
Subsequently, a significant difference in ǃ2GPI levels was observed between non-sepsis  
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(A) Magnifications of purified plasma ǃ2GPI show a circular conformation. (B) Purified 
plasma ǃ2GPI in the presence of gold-labeled (black dots) LPS shows on magnification an 
open fishhook-like shape of ǃ2GPI. This figure was modified from work originally published 
in Blood. C. Agar, P.G. de Groot, M. Mörgelin, S.D.D.C. Monk, G. van Os, J.H.M. Levels, B. 
de Laat, R.T. Urbanus, H. Herwald, T. van der Poll, J.C.M. Meijers. ǃ2-Glycoprotein I: a 
novel component of innate immunity. Blood 2011;117(25):6939-6947. © the American Society 
of Hematology  
Fig. 3. Electron microscopy analysis of ǃ2GPI and LPS. 
and sepsis patients in the intensive care unit. ǃ2GPI levels returned to normal after 
recovery, again suggesting an in vivo interaction between ǃ2GPI and LPS. The reduction in 
ǃ2GPI levels after LPS challenge coincided with an uptake of ǃ2GPI by monocytes. When 
ǃ2GPI binds to LPS, it changes conformation after which the LPS-ǃ2GPI complex is taken 
up by monocytes. Interestingly, the binding of this complex could be dose-dependently 
inhibited by receptor associated protein, indicating that binding of ǃ2GPI is mediated via 
a receptor of the LRP-family (Lutters et al., 2003; Pennings et al., 2006; Urbanus et al., 
2008). 
The ability of native ǃ2GPI to inactivate LPS in vivo might offer opportunities to use ǃ2GPI 
for the treatment of sepsis. ǃ2GPI binds to LPS via domain V of ǃ2GPI. It seems logical to use 
domain V of ǃ2GPI, and not the whole molecule for sepsis treatment. The use of the whole 
protein could induce the formation of auto-antibodies against the cryptic epitope located in 
domain I, which could lead to the development of APS (McNeil et al., 1990). The use of only 
domain V could potentially avoid the development of the pathological auto-antibodies 
against ǃ2GPI. 
A 
B 
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2.2.1 Evolutionary conservation of the LPS binding site in β2GPI 
A survey of the genome sequences of 40 vertebrates and of the fruit fly and roundworm, 
revealed a 14% amino acid homology with 2GPI from the fruit fly Drosophila melanogaster 
and a 17% homology with the roundworm Caenorhabditis elegans, the most primitive 
organisms in which 2GPI could be identified (Agar et al., 2011b). It was found that the 
majority of mammals showed 75% or higher homology for the complete human ǃ2GPI 
amino acid sequence. Remarkably, all mammals except the platypus, showed 100% 
homology for all 22 cysteine residues present in ǃ2GPI, which serve an important structural 
role in protein folding and stability. 
Surface plasmon resonance experiments revealed that the peptide AFWKTDA comprising a 
hydrophobic loop within a large positively charged patch in CCP-V of ǃ2GPI, was able to 
compete for binding of ǃ2GPI to the LPS. This amino acid sequence within domain V was 
completely conserved in all mammals (Agar et al., 2011b). The same amino acid sequences 
also attenuated the inhibition by ǃ2GPI in a cellular model of LPS-induced tissue factor 
expression. This indicated that the AFWKTDA amino acid sequence found in the genome of 
all mammals is the LPS binding region within CCP-V of ǃ2GPI. From this it can be 
concluded that the LPS scavenging function is not only present in humans but evolutionary 
conserved throughout all mammals. This certainly emphasizes an important role for ǃ2GPI 
in biology, explains its high concentration in blood, its conformational change and suggests 
a general role in scavenging of unwanted toxic substances and cells. 
2.3 β2GPI as an overall scavenger 
Analysis of the structure and function of ǃ2-GPI has induced a turn into our 
understanding of the antiphospholipid syndrome. For the last two decades the protein 
ǃ2GPI has been linked mainly to the regulation of coagulation, but recent developments 
(Agar et al., 2011a,b; Gropp et al., 2011) has broadened the focus on ǃ2GPI from 
coagulation to innate immunity. For many years the characterization of the antibodies 
was the line of approach to understand the pathophysiology of the syndrome, 
unfortunately with little success. 
During the last years, more and more evidence has become available that ǃ2GPI is a more 
general scavenger in our circulation. Maiti et al (2008) showed a ǃ2GPI-dependent 
phosphatidylserine (PS) expressing apoptotic cell uptake by macrophages. Binding of 
ǃ2GPI to these cells caused recognition and uptake of the ǃ2GPI-apoptotic cell complex 
by the LRP receptor on macrophages. The receptor for binding to apoptotic cells was 
determined to be the Ro 60 receptor (Reed et al., 2008, 2009). Furthermore, another study 
suggested that the binding of ǃ2GPI to PS-expressing procoagulant platelet 
microparticles might promote their clearance by phagocytosis (Abdel-Monem et al., 
2010). 
Blood contains microparticles (MPs) derived from a variety of cell types, including 
platelets, monocytes, and endothelial cells. MPs are formed from membrane blebs that are 
released from the cell surface by proteolytic cleavage of the cytoskeleton (Owens & 
Mackman, 2011). MPs may be procoagulant because they provide a membrane surface for 
the assembly of components of the coagulation protease cascade. Importantly, 
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procoagulant activity is increased by the presence of anionic phospholipids, particularly 
phosphatidylserine (PS), and the procoagulant protein tissue factor (TF), which is the 
major cellular activator of the clotting cascade (Owens & Mackman, 2011). Since 
microparticles are considered to be important in coagulation, the efficient recognition and 
removal of these particles is critical for the maintenance of homeostasis and resolution of 
inflammation. 
It has been shown that autoantibodies to ǃ2GPI inhibit this uptake of microparticles and 
bound TF to induce a procoagulant state (Abdel-Monem et al., 2010). The role of TF was 
studied in a renal injury mouse model that shared many features with thrombotic 
microvascular disease (Seshan et al,. 2009). Both complement-dependent and complement-
independent mechanisms were found to be responsible for endothelial activation and 
microvascular disease induced by antiphospholipid antibodies obtained from APS patients. 
The presence of antibodies against ǃ2GPI showed a disturbed uptake of microparticles 
leading to increased TF in the circulation, which on its turn caused renal injury. It was also 
shown that mice expressing low levels of TF were protected against this injury induced by 
the presence of the antiphospholipid antibodies (Seshan et al., 2009). 
3. Conclusions and future perspective 
In conclusion, over the last few years a wealth of interesting data has become available that 
increased our knowledge on ǃ2GPI. The discovery of the native state of ǃ2GPI as a circular 
protein explained the important paradox that antibodies and protein could circulate 
separately in blood. Also, other previously ascribed functions were probably functions of 
the protein induced by the harsh method of purification after which only the open, 
activated, conformation of the protein was obtained. Furthermore, the potential of 
antibodies, anionic phospholipids, LPS and probably even more agents to switch the 
conformation of ǃ2GPI from a circular to an open activated conformation has given a clue to 
its role as scavenger, since the open conformation can bind to and subsequently be taken up 
by cells such as monocytes and macrophages. A role of ǃ2GPI as overall scavenger in 
coagulation and innate immunity, two complex processes that are highly intertwined, may 
provide clues to one of the remaining questions in APS research, namely how binding of 
antiphospholipid antibodies to ǃ2GPI result in thrombosis. An interesting option is that 
ǃ2GPI disturbs the uptake of microparticles resulting in a procoagulant state due to 
increased levels of TF and anionic phospholipids in the circulation. If the formation and 
presence of antibodies against ǃ2GPI also disturbs the scavenging function of ǃ2GPI still 
needs to be proven. 
By identifying agents that can switch the conformation of ǃ2GPI, other areas of biology can 
be identified where ǃ2GPI might play a role. With the evolutionary conservation that was 
observed for the protein, its role in biology must be significant. It goes beyond saying that 
the appreciation of the different conformations and the ability to switch conformation has 
provided an important basis for research in this area. 
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